In 2019, a California jury awarded $2 billion to a couple who claimed Monsanto’s Roundup weedkiller caused their cancer. The judge later reduced it. The case eventually settled as part of Bayer’s $10.9 billion Roundup resolution. But the number — two billion dollars, from twelve people in a courtroom — entered the bloodstream of American litigation and hasn’t left.
Plaintiff attorneys call them “nuclear verdicts”: jury awards of $10 million or more that detonate the normal settlement calculus. The American Tort Reform Association has tracked their rise with alarm, reporting that the median nuclear verdict has climbed steadily while their frequency has roughly tripled over the past decade. In trucking litigation alone, verdicts exceeding $10 million went from a rarity to a regular occurrence, with some years seeing dozens.
For anyone who values lawsuits — litigators, insurers, litigation funders, corporate defendants — nuclear verdicts have broken the models. Settlement valuation used to be an actuarial exercise: look at comparable outcomes, discount for risk, negotiate within a range. Now every valuation carries a tail risk that the range itself is wrong.
How the math broke
Traditional settlement valuation works like this. Take the expected verdict value — the probability-weighted outcome if the case goes to trial. Discount it for the time value of money, the cost of getting there, and the risk of losing entirely. The result is a settlement range both sides can live with. It works beautifully when verdicts follow a predictable distribution.
Nuclear verdicts destroy that distribution. They’re not just large. They’re unpredictably large — driven less by the facts of the case than by jury anger, attorney theatrics, and what researchers call “anchoring,” where the plaintiff’s ask sets a psychological reference point that pulls the award upward regardless of the evidence.
The U.S. Chamber of Commerce’s Institute for Legal Reform published a landmark study documenting the trend, finding that the median nuclear verdict against corporate defendants had risen into the tens of millions, with a meaningful share exceeding $100 million. More importantly, the study found that the factors predicting a nuclear verdict had less to do with the severity of the plaintiff’s injury than with the defendant’s perceived wealth and the plaintiff attorney’s reptile-theory tactics — trial strategies designed to trigger jurors’ survival instincts by framing the defendant as a threat to community safety.
This is what makes nuclear verdicts so corrosive to settlement math. If verdict size correlates with corporate revenue rather than actual harm, then every large company is a target regardless of the merits. The settlement value of a case becomes a function of the defendant’s market cap, not the plaintiff’s damages.
The industries in the blast radius
No sector is immune, but some are getting hit harder. Commercial trucking leads the grim leaderboard — the combination of sympathetic plaintiffs (often families of accident victims), corporate defendants with insurance policies juries can see, and reptile-theory-friendly fact patterns (tired drivers, skipped inspections) makes trucking cases ideal nuclear verdict fuel. The American Transportation Research Institute has documented the trend extensively, warning that nuclear verdicts are driving insurance premiums to levels that threaten the viability of smaller carriers.
Product liability is next. The Roundup litigation, the Johnson & Johnson talc cases (with verdicts in the billions before appellate reduction), and the 3M earplug mass tort (which settled for $6 billion in 2023) have reset expectations for what product cases are “worth.” Medical malpractice, historically somewhat insulated by tort reform caps in many states, is seeing nuclear verdicts in jurisdictions without caps — particularly in obstetrics and surgical cases with catastrophic outcomes.
Even employment litigation, once a world of modest settlements, has seen eight-figure verdicts become almost routine in California and New York. The combination of #MeToo-era jury attitudes and uncapped punitive damages in some jurisdictions has transformed the settlement calculus for every HR department in America.
The defense bar’s counteroffensive
Corporate defendants haven’t been passive. The response has unfolded on three fronts.
First, tort reform. States including Florida, Georgia, and Iowa have passed significant reforms in recent years — tightening standards for expert testimony, limiting the admissibility of inflated medical bills (a practice called “phantom damages”), and capping certain categories of damages. Florida’s 2023 tort reform package, HB 837, was among the most sweeping in decades, and early data suggests it’s having a measurable impact on filing patterns.
Second, trial tactics. Defense firms have gotten dramatically better at countering reptile theory, developing their own juror psychology playbooks. The most effective approach, according to trial consultants, isn’t to argue the defendant is a good corporate citizen — jurors see through that. It’s to give jurors a rational framework for damages before the plaintiff’s attorney gives them an emotional one. He who anchors first often wins.
Third, venue strategy. Where a case is filed matters enormously. Plaintiff attorneys forum-shop for jurisdictions known for generous juries — the infamous “judicial hellholes” identified annually by the American Tort Reform Association. Defense attorneys fight venue aggressively, and the rise of multidistrict litigation has centralized some mass torts in more predictable forums.
The funder’s perspective
Litigation funders — the Burford Capitals and Omni Bridgeways of the world — have a complicated relationship with nuclear verdicts. On one hand, larger potential awards mean larger potential returns on funded cases. On the other, unpredictability is the enemy of portfolio construction. A funder modeling expected returns across 50 cases needs the distribution to be roughly normal. Nuclear verdicts make it fat-tailed.
The sophisticated funders have adapted by pricing the tail explicitly. Rather than treating nuclear verdicts as outliers to be ignored, they model them as low-probability, high-impact events — essentially buying a lottery ticket embedded in every case. This actually increases settlement values in funded cases, because the funder’s walk-away price incorporates a probability of nuclear upside that a risk-averse individual plaintiff might not.
It’s a strange equilibrium. Nuclear verdicts make cases harder to value, which makes settlements harder to reach, which means more cases go to trial, which produces more nuclear verdicts. The cycle feeds itself.
The counterargument: maybe juries are right
Here’s the uncomfortable possibility that the tort reform movement doesn’t like to discuss. Maybe nuclear verdicts aren’t a malfunction. Maybe they’re a correction.
Consider the economics. For decades, corporate defendants calculated that it was cheaper to pay occasional settlements than to fix systemic safety problems. The Ford Pinto memo — where Ford’s cost-benefit analysis valued a human life at $200,000 and decided against an $11-per-car fix — is the canonical example, but the logic persisted. If the expected legal cost of killing someone is lower than the cost of preventing it, the rational corporation doesn’t prevent it.
Nuclear verdicts change that calculus. A $100 million verdict doesn’t just compensate the plaintiff. It sends a signal to every boardroom in America that the cost of negligence just went up by an order of magnitude. From a deterrence perspective — which is, after all, one of tort law’s stated purposes — that might be exactly what the system is supposed to do.
The problem is proportionality. A system that awards $10 million for a fender-bender because the defendant is a Fortune 500 company isn’t deterring negligence. It’s running a lottery. And lotteries don’t produce safety. They produce fear, higher insurance premiums, and defensive corporate behavior that helps no one.
What this means for settlement valuation
Anyone valuing a lawsuit in 2026 needs a nuclear verdict framework, not just a comparable-settlements database. That means asking three questions every defense-side valuation used to skip.
First, what’s the venue’s nuclear verdict history? A case worth $500,000 in federal court in Delaware might be worth $5 million in state court in Los Angeles County. Venue isn’t just a procedural detail anymore. It’s the single largest variable in the valuation.
Second, what’s the reptile-theory exposure? Cases involving safety, children, or corporate knowledge of risk carry nuclear potential that has nothing to do with the medical bills. The valuation needs a separate line item for jury anger.
Third, what’s the defendant’s “nuclear profile”? Large revenue, consumer-facing brand, prior bad acts in the news — these are the characteristics that turn a routine case into a headline verdict. The most sophisticated insurers now score defendants on nuclear risk the way credit agencies score borrowers on default risk.
Settlement valuation used to be about predicting what a reasonable jury would do. Now it’s about predicting what an angry jury might do. That’s a harder problem, a more expensive one, and — for the companies building tools to solve it — a much bigger opportunity.
Settlement valuation in the nuclear verdict era requires better data — settlementvaluation.com is available for acquisition by the platform built to provide it.
"A lawsuit is worth what a disciplined buyer would pay for it — and the most disciplined buyers in the business reject 95% of what they see."